Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care

Go online to PeerView.com/WCP860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Psoriasis is a widely prevalent, chronic, systemic,
immune-mediated disease that substantially impairs patients’
physical health, quality of life and work productivity. Nearly
one-quarter of people with psoriasis have cases that are considered
moderate to severe. Despite the availability of effective systemic
therapy, many patients remain undertreated or even untreated and
are dissatisfied with current treatments. In this activity, two
experts review the rationale for TYK2 inhibition as a novel
approach for the treatment of moderate to severe psoriasis. In
addition, key information for the first-in-class, oral, selective
TYK2 inhibitor will be provided, as well as the key roles that
advanced practice clinicians (eg, NPs, PAs) play in the management
of patients with psoriasis in an era of expanding oral treatment
options. Upon completion of this activity, participants should be
better able to: Describe the rationale for targeting the TYK2
kinase as it relates to novel approaches for the treatment of
moderate to severe psoriasis; Identify patients with psoriasis who
are most likely to benefit from novel oral treatments; Select among
established and novel therapies to personalize management plans for
patients with psoriasis based on efficacy and safety evidence and
guidelines; and Facilitate care coordination and communication with
patients and other healthcare team members that fosters a whole
patient approach to managing psoriasis.